Inhalation Anesthesia Market Type, End-User, and Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
An Inhalation
Anesthesia Market is a chemical substance with general anaesthetic
effects that can be inhaled. They are given using a face mask, laryngeal mask
airway, or tracheal tube that is linked to an anaesthetic vaporiser and an
anaesthetic delivery system. Volatile anaesthetic drugs such as isoflurane,
sevoflurane, and desflurane, as well as anaesthetic gases such as nitrous oxide
and xenon, are of recent therapeutic interest.
The global Inhalation
Anesthesia Market is expanding rapidly as the prevalence of chronic
disease and the global geriatric population grows. Furthermore, an increase in
the number of surgical procedures is likely to drive market expansion. However,
factors such as inhalation anaesthetic side effects and the increased use of
generic inhalation anaesthetic medications are likely to stifle growth in the
worldwide inhalation anaesthetics market.
Volatile anaesthetic drugs have
the property of being liquid at room temperature but quickly evaporating when
inhaled. These agents all have the trait of being extremely hydrophobic (i.e.,
as liquids, they are not freely miscible with water, and as gases they dissolve
in oils better than in water). The ideal volatile anaesthetic agent provides
seamless and consistent induction and maintenance of general anaesthesia while
having little effect on other organ systems. Furthermore, it is odourless or
pleasant to inhale; safe for all ages and during pregnancy; not metabolized;
rapid in onset and offset; powerful; and safe for operating room staff exposure.
It is also inexpensive to produce; simple to carry and store; has a long shelf
life; and is simple to administer. Monitor with existing equipment; resistant
to light, plastics, metals, rubber, and soda lime; non-flammable and
non-hazardous to the environment none of the present agents are optimal, though
many have some desirable properties. Sevoflurane, for example, is pleasant to
inhale and has a quick onset and offset. It is also suitable for people of all
ages. However, it is expensive (about 3 to 5 times more expensive than
isoflurane) and just half as effective.
Sevoflurane, desflurane,
isoflurane, and halothane are the drugs that make up the inhalation anaesthetic
market. Sevoflurane led the inhalation anaesthetic market in 2021 because it is
more potent, quickly acting, and has faster emergence and recovery than other
medications on the market; yet, it is more expensive than its competitors.
Because of these qualities, surgeons favour sevoflurane for induction and
maintenance of anaesthesia during surgical procedures. Isoflurane is predicted
to expand at the fastest rate during the projection period. When fresh gas flow
rates are taken into account, sevoflurane and desflurane are two to three times
more expensive than isoflurane. As a result of the presence of a metabolite,
isoflurane is the favoured option of anesthesiologists in poor nations for
inhalation general anaesthesia.
Companies covered:
AbbVie Inc., Baxter, Merck KgaA, Trokiaa, Piramal Enterprises Ltd., Lunan Pharmaceutical Group Co. Ltd., Hikma Pharmaceuticals PLC, Fresenius Kabi AG (Fresenius SE& Co. KGaA), Jiangsu Hengrui Medicine Co. Ltd., and Dechra Pharmaceuticals PLC
Comments
Post a Comment